This study aims to evaluate the therapeutic potential of Ivermectin, an FDA-approved antiparasitic drug commonly used for laboratory animals, for its anti-cancer efficacy. Specifically, the investigation will focus on its effects in a 4NQO-induced tongue tumor model of oral squamous cell carcinoma (OSCC) in C57BL/6 mice. The study will assess Ivermectin’s anti-tumor activity both as a monotherapy and in combination with Celecoxib, Erlotinib, and Methotrexate, clinically approved drugs routinely used in the metronomic chemotherapy of head and neck cancers.

This study focuses on the development and characterization of a modified 4NQO-induced tongue tumour model of oral squamous cell carcinoma (OSCC) in C57BL/6 mice. Unlike the conventional continuous 4NQO exposure for 16 weeks followed by a no-treatment phase, this protocol employs a thrice-weekly dosing schedule for 28 weeks. The strategic modification was designed to reduce 4NQO-associated toxicity and mortality while creating a therapeutic window for administering chemopreventive agents in an ad libitum setting.

Head and neck squamous cell carcinomas (HNSCCs) is a complex and heterogeneous disease regulated at multiple levels and associated with high mortality and morbidity. HNSCCs are related to environmental risk factors, especially excessive tobacco and alcohol consumption. Oral squamous cell carcinomas (OSCCs) are the prevalent forms of HNSCC, representing approximately 90% of all tumors in this region. The high mortality associated with OSCC is related mainly to the locoregional advancement of the disease.